Downregulation of LGR4 decreases ARPE-19 cell migration. by Qiang Hou (495704)

SDG decreases p70S6K1 and increases AMPK protein expression in iron treated H9c2 cells. by Stephanie Puukila (568109)

The variable importance of each histone modification in determining RNA expression levels was obtained by random forest as mean decrease in node impurity. by Yayoi Natsume-Kitatani (211588)

Serum samples and 50% NAI values. Serum samples taken from CEIRS study. by Harrison Powell (9040128)

Kat60 lacking the MIT domain does not disassemble microtubules at low levels of accumulation in cells. by Kyle D. Grode (725568)

Kat60 lacking the MIT domain disassembles microtubules at high levels of accumulation in cells. by Kyle D. Grode (725568)

Inducible expression of Kat60 results in measurable microtubule disassembly in our single-cell assay. by Kyle D. Grode (725568)

Inhibition of the mitochondrial fission decreases mtROS production. by Dong Ma (584680)

Effect of cilostazol on liver TNF-α (A), IL-6 (B), NFκβ (C) and TGFβ (D) in TAA-induced fibrosis in rats. by Sally A. El Awdan (710176)

Inhibition of TMEM16A decreased SW620 cell migration and invasion. by Yujie Sui (549090)

PNs, ORNs and LNs response to a short (50 ms) pulse, similar results of Fig 4. by Mario Pannunzi (553941)

Knockdown of AR expression decreases the efficiency of KSHV infection in endothelial cells. by Xing Wang (154377)

“…(g, h) Knockdown of AR and EphA2 expression decreases nuclear LANA expression in SLK cells, as determined by an immunofluorescence assay and quantitative analysis by Image J software. …”

Mean plasma concentration profiles of oseltamivir and oseltamivir carboxylate after a single oral administration of oseltamivir at 75 mg. by Jaeseong Oh (3947381)

Sensitivity analysis for IC₅₀ and <i>ε</i>_max as a function of measurement time. by Hope Murphy (8843516)

Multiple logistic regression model exploring factors associated with >50% seizures reduction at month 4. by Michel Mandro (2637532)

Table_1_Anti-Mitochondrial Antibody Titers Decrease Over Time in Primary Biliary Cholangitis Patients With Ursodeoxycholic Acid Therapeutic Response: A Cohort Study Followed Up to... by Ming-Ling Chang (44638)

“…Patients with baseline cirrhosis (2.78 ± 2.56 vs. 6.84 ± 9.00 mg/dL, p=0.024) and UDCA nonresponders (2.54 ± 2.19 vs. 4.51 ± 6.99 mg/dL, p=0.006) had increased total bilirubin levels while patients without cirrhosis (AST: 91.5 ± 84.5 vs. 58.9 ± 43.7 U/L, p<0.001; ALT: 107.3 ± 122.5 vs. 50.7 ± 36.8 U/L, p<0.001) and UDCA responders (AST: 83.8 ± 101.3 vs. 45.58 ± 38.42 U/L, p=0.014; ALT: 95.10 ± 144.6 vs. 39.12 ± 30.65 U/L, p=0.009) had decreased aminotransferase levels. …”

Image_1_Anti-Mitochondrial Antibody Titers Decrease Over Time in Primary Biliary Cholangitis Patients With Ursodeoxycholic Acid Therapeutic Response: A Cohort Study Followed Up to... by Ming-Ling Chang (44638)

“…Patients with baseline cirrhosis (2.78 ± 2.56 vs. 6.84 ± 9.00 mg/dL, p=0.024) and UDCA nonresponders (2.54 ± 2.19 vs. 4.51 ± 6.99 mg/dL, p=0.006) had increased total bilirubin levels while patients without cirrhosis (AST: 91.5 ± 84.5 vs. 58.9 ± 43.7 U/L, p<0.001; ALT: 107.3 ± 122.5 vs. 50.7 ± 36.8 U/L, p<0.001) and UDCA responders (AST: 83.8 ± 101.3 vs. 45.58 ± 38.42 U/L, p=0.014; ALT: 95.10 ± 144.6 vs. 39.12 ± 30.65 U/L, p=0.009) had decreased aminotransferase levels. …”

(A) Experimental timeline and (B) behavioural results (mean ± SEM) in Experiment 2 on the effect of adaptation to a decrease and to an increase in height of the ball drop. by Ana Tajadura-Jiménez (315994)

The Dose–Response Decrease in Heart Rate Variability: Any Association with the Metabolites of Polycyclic Aromatic Hydrocarbons in Coke Oven Workers? by Xiaohai Li (136211)

“…After adjustment for potential confounders, elevation per interquartile range (IQR) (1.81 µg/mmol creatinine) of urinary 2-hydroxynaphthalene was associated with a 5.46% (95% CI, 2.50–8.32) decrease in standard deviation of NN intervals (SDNN). …”

Mean reaction times in ms to select the infant or the adult target (± SEM). by Sarah K. C. Holtfrerich (3353693)